Natixis Alnylam Pharmaceuticals, Inc. Transaction History

Natixis

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$143.31 - $247.0 $56,034 - $96,577	-391 Reduced 57.33%	291 $70,000
Q1 2024 May 13, 2024	BUY	$146.51 - $198.2 $99,919 - $135,172	682 New	682 $101,000
Q4 2022 Feb 13, 2023	BUY	$185.53 - $241.31 $44.2 Million - $57.5 Million	238,476 Added 105.5%	464,510 $110 Million
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $30.2 Million - $50.6 Million	218,295 Added 2820.71%	226,034 $45.3 Million
Q2 2022 Aug 12, 2022	BUY	$120.42 - $169.29 $647,016 - $909,595	5,373 Added 227.09%	7,739 $1.13 Million
Q1 2022 May 13, 2022	SELL	$127.18 - $173.91 $12.9 Million - $17.7 Million	-101,696 Reduced 97.73%	2,366 $386,000
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $246,679 - $323,562	1,546 Added 1.51%	104,062 $17.6 Million
Q3 2021 Nov 12, 2021	BUY	$169.75 - $207.73 $16 Million - $19.5 Million	94,044 Added 1110.06%	102,516 $19.4 Million
Q2 2021 Aug 13, 2021	BUY	$128.63 - $176.89 $252,243 - $346,881	1,961 Added 30.12%	8,472 $1.44 Million
Q1 2021 May 14, 2021	BUY	$126.83 - $175.69 $573,905 - $794,997	4,525 Added 227.84%	6,511 $919,000
Q4 2020 Feb 12, 2021	SELL	$122.97 - $147.0 $75,749 - $90,552	-616 Reduced 23.67%	1,986 $258,000
Q3 2020 Nov 12, 2020	BUY	$121.19 - $165.49 $315,336 - $430,604	2,602 New	2,602 $379,000

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.2B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.